Telmisartan, Amlodipine and Flow Mediated Dilation

Inclusion Criteria: * Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation. * Age 35 and older. * Male and female, treated and treatment-naive patients with uncontrolled hypertension (defined as 20/10 mmHg above target BP of \<140/90 mmHg \[\<130/80 mmHg for renally impaired and/ or diabetics patients\]) * Male and female treated patients with controlled hypertension (defined as target BP \< 140/90 mmHg \[ \< 130/80 mmHg for renally impaired and/ or diabetics patients\]) * \> 3 cardiovascular risk factors CVRFs and/or metabolic syndrome and/or diabetes mellitus and/or end organ damage Exclusion Criteria: 1. Pretreatment with Telmisartan within the last 3 months. 2. Pretreatment with Amlodipine, Diuretics and AT1Blocker/ACEInhibitor within the last 3 months 3. Myocardial infarction within last 6 months. 4. Previous stroke or hemodynamically relevant stenosis of carotic arteria (\>70%). 5. Previous cardial or peripheral bypass surgery within last 6 months. 6. PAD stadium III - IV n.F. 7. Chronic heart failure NYHA III- IV. 8. Unstable angina. 9. Known intolerance to angiotensin receptor blockers, diuretics or dihydropyridine calcium channel blocker. 10. Pre-menopausal women (last menstruation ≤1 year prior to signing informed consent) who: 1. are not surgically sterile; or 2. are nursing, or 3. are pregnant, or 4. are of childbearing potential and are NOT practicing acceptable methods of birth control, or do NOT plan to continue practicing an acceptable method throughout the trial. The only acceptable methods of birth control are: 5. Intra-Uterine Device (IUD) 6. Oral 7. implantable or injectable contraceptives 8. Estrogen patch 9. Hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study 11. Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 a.m. 12. Known or suspected secondary hypertension (e.g., renal artery stenosis or phaeochromocytoma) 13. Mean in-clinic seated cuff SBP ≥180 mmHg and/or DBP ≥110 mmHg 14. Renal dysfunction as defined by the following laboratory parameters: 15. Serum creatinine \>3.0 mg/dL (or \>265 μmol/L) and/or known estimated creatinine clearance of \<30 ml/min and/or clinical markers of severe renal impairment. 16. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney 17. Clinically relevant hypokalemia or hyperkalemia (i.e., \<3.0 or \>5.5 mEq/L, may be rechecked for suspected error in result) 18. Uncorrected sodium or volume depletion 19. Primary aldosteronism 20. Hereditary fructose intolerance 21. Biliary obstructive disorders (e.g., cholestasis) or hepatic insufficiency 22. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the Investigator 23. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve 24. Patients whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥10% 25. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists 26. History of drug or alcohol abuses within six months prior to signing the informed consent form 27. Concomitant administration of any medications known to affect BP, except medications allowed by the protocol 28. Any investigational drug therapy within one month of signing the informed consent 29. Known contraindication to any component of the trial drugs (telmisartan, amlodipine, olmesartan, hydrochlorothiazide) 30. History of non-compliance or inability to comply with prescribed medications or protocol procedures 31. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication